Pfizer (PFE) Assets Average (2009 - 2026)

Pfizer has disclosed Assets Average across 18 years of filings, most recently posting $208.1 billion for Q1 2026.

• In Q1 2026, Assets Average fell 1.25% year-over-year to $208.1 billion; the TTM figure through Mar 2026 stood at $208.1 billion (down 1.25% YoY), while the FY2025 annual figure was $210.8 billion, down 2.61% from the prior year.
• Assets Average steadied at $208.1 billion in Q1 2026, from $208.6 billion in the prior quarter.
• Over the last five years, Assets Average for PFE reached as high as $223.8 billion in Q1 2024 and fell as low as $118.2 billion in Q4 2022.
• The 5-year median for Assets Average is $208.1 billion (2026), against an average of $198.3 billion.
• Annual changes were most pronounced in 2023 — Assets Average jumped 85.4% — and 2025, when it slipped 5.85%.
• A 5-year view of Assets Average shows it stood at $119.1 billion in 2022, then jumped by 85.4% to $220.8 billion in 2023, then retreated by 1.95% to $216.4 billion in 2024, then decreased by 3.63% to $208.6 billion in 2025, then decreased by 0.24% to $208.1 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $208.1 billion, $208.6 billion, and $207.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.